Trials / Completed
CompletedNCT02274025
NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients
Collection of Lung Malignant Tissue for the Validation of a Novel Technology to Identify Oncogenic Mutations and Personalized Medicine
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Fore Biotherapeutics · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
NovellusDx technology identifies tumor-specific driver mutations, but unlike sequencing-based tests, NovellusDx has a functional assay that detects dis-regulated translocation of mutated signaling proteins to the nucleus. This allows NovellusDx to identify functionally-impactful driver mutations regardless of whether the mutation has previously been described or linked to a tumor type.
Conditions
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-10-01
- Completion
- 2016-10-01
- First posted
- 2014-10-24
- Last updated
- 2018-03-29
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02274025. Inclusion in this directory is not an endorsement.